Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma A Single-Center, Open-Label, 2-Year Randomized Clinical Trial

Full text
Author(s):
Batista, Rafael L. [1] ; Musolino, Nina R. C. [1] ; Cescato, Valter A. S. [1] ; da Silva, Gilberto O. [1] ; Medeiros, Raphael S. S. [2] ; Herkenhoff, Clarissa G. B. [1] ; Trarbach, Ericka B. [3] ; Cunha-Neto, Malebranche B. [1]
Total Authors: 8
Affiliation:
[1] FMUSP, Hosp Clin, Inst Psychiat IPq, Div Funct Neurosurg, Sao Paulo, SP - Brazil
[2] FMUSP, Hosp Clin, Div Pathol Anat, Sao Paulo - Brazil
[3] FMUSP, Hosp Clin, Discipline Endocrinol, Lab Cellular & Mol Endocrinol, LIM25, Sao Paulo, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS; v. 42, n. 2, p. 221-227, FEB 2019.
Web of Science Citations: 1
Abstract

Background: Complete tumor removal by transsphenoidal surgery is usually difficult for large nonfunctioning pituitary adenomas (NFPAs). A validated medical treatment may be useful for their management. This study evaluates the clinical efficacy of the dopaminergic agonist cabergoline for residual NFPA. Design, Setting, and Participants: We conducted a randomized, parallel, open-label clinical trial that compared cabergoline with nonintervention in patients with residual NFPA after transsphenoidal surgery over 2 years. The primary outcome was clinical efficacy (tumor reduction). The secondary outcome was the relationship between tumor dopamine D2 receptor (D2R) expression and clinical responsiveness. Tumor measurements and clinical evaluations were performed every 6 months. Results: In total, 59 and 57 individuals were randomly assigned to the study and control groups, respectively. At the end of the study, residual tumor shrinkage, stabilization, and enlargement were observed in 28.8%, 66.1%, and 5.1% of patients, respectively, in the medical-therapy group and in 10.5%, 73.7%, and 15.8% of patients, respectively, in the control group (P=0.01). The progression-free survival rate was 23.2 and 20.8 months for the study and control groups, respectively (P=0.01). D2R was not associated with cabergoline responsiveness. No major side effects were related to cabergoline use. Conclusions: Cabergoline was an effective drug for treating residual NFPA, and its use was associated with a high rate of tumor shrinkage ( NCT03271918). (AU)

FAPESP's process: 14/16327-1 - Expression of D2 receptor in clinically nonfunctioning pituitary adenomas and its correlation with cabergoline treatment
Grantee:Ericka Barbosa Trarbach
Support Opportunities: Regular Research Grants